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Introduction {#sec1}
============

Human male germ cell tumors (GCTs) are thought to originate in primordial germ cells (PGCs) most likely by a mechanism similar to that recently described for the origin of teratocarcinomas in strain 128 family mice ([@bib11]). The key driver for this process is suggested to be upregulation of genes in the pathways controlling pluripotency and proliferation, such as *NANOG*, *CCND2*, and *RASK2* that map to chromosome 12p ([@bib3], [@bib16]). GCTs comprise two main subsets, seminoma (SEM) and nonseminoma (NS), with a common precursor, germ cell neoplasia in situ (GCNIS). SEM is unipotent whereas the NS subset embryonal carcinoma (EC) is pluripotent, analogous to the blastocyst ([@bib1]), and has a gene-expression profile (GEP) similar to that of embryonic stem cells (ESCs) ([@bib26], [@bib14]). EC differentiates to extraembryonic (choriocarcinoma, yolk sac tumor) and embryonic (teratoma) lineages ([@bib3]). Comparison of GEPs of human PGC (hPCG)-like cells derived in vitro from ESCs, gonadal GCs, and the SEM cell line TCam-2 suggested that SEM arises in PGCs and hence is a good model system to investigate hPGC biology ([@bib13]). *SOX17* was shown to be the key specifier of hPGC fate, with the downstream *PRDM1* repressing mesendodermal genes ([@bib13]).

The core pluripotency regulatory master transcription factors (TFs) *POU5F1* and *NANOG* are expressed in both EC and SEM, whereas *SOX2* is repressed in hPGCs ([@bib25], [@bib13]), GCNIS, and SEM ([@bib16]). The molecular mechanism of *SOX2* repression in the hPGC-GCNIS-SEM lineage has so far not been characterized. We show here that *SOX2* repression in TCam-2 cells is due to the co-occupation by the Polycomb group (PcG) proteins and the repressive chromatin mark H3K27me3 near its transcription start site (TSS). We further show that the occupancy of H3K27me3 decreases when *UTX*, a H3K27-specific demethylase, is recruited to the *SOX2* promoter in response to retinoid signaling, leading to *SOX2* transcriptional derepression and induction of neuronal genes, consistent with its function as a neuroectodermal effector ([@bib30], [@bib31]). Thus, *SOX2* repression in TCam-2/SEM is imposed by PcG and its derepression is regulated by *UTX*. These data are consistent with a model of hPGC development initiated by *SOX17*, with *PRDM1* repressing mesodermal genes and *SOX2* repression inhibiting neuroectodermal genes.

Although murine and human PGCs re-express pluripotency genes following specification, pluripotency remains latent and becomes functional only when PGCs are cultured in vitro as embryonic germ cells or transform in vivo as GCTs ([@bib20]). By analysis of GEPs of SEM and EC, we show here that the functional pathways of SEM reflect their derivation from PGCs, while those of EC, also derived from PGCs, reflect re-establishment of pluripotency in the transformed PGCs. These data are of value in understanding the biology of hPGCs and regulation of the pluripotency state in the unique GCT system.

Results {#sec2}
=======

Functional Programs in SEM and EC Reflect Their Development from PGCs following Malignant Transformation and Re-establishment of Pluripotency {#sec2.1}
---------------------------------------------------------------------------------------------------------------------------------------------

Despite their common origin from transformed hPGCs, SEM retains the germline characteristic of latent pluripotency while EC attains embryonal-like pluripotency. As such, SEM and EC provide an opportunity to identify the functional pathways that underlie the latent and patent pluripotency of the two PGC-derived tumor states. Toward this end, we performed significance analysis for microarray (SAM) and gene ontology (GO biological process) analyses of the upregulated and downregulated genes in the GEPs of 41 EC and 16 SEM tumors in comparison with those of five normal testis controls. These GEPs were a subset of the GEP data of a larger cohort of GCTs representing all histologic and developmental categories and normal testis biopsies that we previously published ([@bib15], [@bib16], [@bib17]). SAM analysis showed that upregulated genes in SEM included the GC genes *KIT*, *CD38*, *TNAP*, *SOX17*, *NANOS*, *TFAP2C*, and *UTF1* consistent with their PGC derivation as previously shown in the TCam-2 SEM cell line ([@bib13]) ([Tables S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"}). GO analysis identified significantly upregulated categories in SEM related to DNA integrity (p = 4.5 × 10^−4^) and damage response (4.5 × 10^−5^), regulation of cell morphogenesis (p = 4.86 × 10^−4^), and RNA processing (3.7 × 10^−10^), whereas those in EC related to stem cell maintenance (p = 0.003), cell morphogenesis (p = 4.2 × 10^−7^), multicellular organismal process (p = 0.0002), anatomic structure morphogenesis (p = 8.38 × 10^−7^), and response to wounding (p = 8.59 × 10^−10^) ([Figure 1](#fig1){ref-type="fig"}). In addition, upregulated categories representing cell proliferation (pSEM = 1.13 × 10^−3^; pEC = 0.0038) and negative regulation of apoptosis (pSEM = 3.34 × 10^−4^; pEC = 4.05 × 10^−5^) were common to both subsets, reflecting their transformed state ([Figure 1](#fig1){ref-type="fig"}). The downregulated categories were remarkably similar in both subsets and were represented by gamete generation (pSEM = 6.24 × 10^−44^; pEC = 2.28 × 10^−45^), spermatogenesis (pSEM = 7.24 × 10^−52^; pEC = 3.43 × 10^−57^), spermatid differentiation (pSEM = 2.68 × 10^−12^; pEC = 2.8 × 10^−13^), meiotic cycle (pSEM = 3.24 × 10^−12^; pEC = 3.16 × 10^−12^), and reproduction (pSEM = 7.58 × 10^−31^; pEC = 1.06 × 10^−30^) ([Figure 1](#fig1){ref-type="fig"}). These data represent elucidation of regulatory pathways in these two subsets.

Computationally Identified *SOX2* Targets Involved in Pluripotency and Differentiation Pathways Are Significantly Enriched in EC Compared with SEM {#sec2.2}
--------------------------------------------------------------------------------------------------------------------------------------------------

We recently assembled a complete in vivo GCT TF interactome (GCT^Net^) based on the GEPs of tumor biopsies using the Algorithm for the Reconstruction of Accurate Cellular Networks (ARACNe) ([@bib18]). GCT^Net^, comprising 1,305 TFs and ∼250,000 interactions, which encompassed all the functional pathways operating in this tumor system and inferred all the expressed target genes of the entire complement of TFs. This analysis showed that *POU5F1*, *NANOG*, and *SOX2* had 338, 376, and 307 ARACNe-inferred individual target genes, respectively. In addition, *POU5F1* and *NANOG* shared 127 common targets, whereas *POU5F1* and *SOX2*, and *NANOG* and *SOX2*, shared 40 common targets. We validated the ARACNe-inferred targets of these three genes by analysis of GEP following their short hairpin RNA-mediated knockdown (KD) and by genome sequencing following chromatin immunoprecipitation (ChIP) in EC-derived NT2/D1 cells, thus establishing their role as mechanistic transcriptional targets ([@bib18]). We now performed GEP analysis of NT2/D1 and TCam-2 cells and assessed the enrichment of the previously identified ARACNe-inferred targets of *POU5F1*, *NANOG*, and *SOX2* in genes that are differentially expressed between the two cell lines by gene set enrichment analysis (GSEA) ([@bib23], [@bib27]). As shown in [Figure 2](#fig2){ref-type="fig"}A, this analysis clearly shows that whereas target enrichment was significant for all three TFs between NT2/D1 and TCam-2 cell lines, *SOX2* targets showed enrichment in overexpressed genes in NT2/D1 compared with TCam-2, while *NANOG* and *POU5F1* showed opposite enrichment, i.e., in underexpressed genes. Whereas a GO analysis of GSEA targets of *SOX2* overexpressed in TCam-2 cells identified no significant categories, that of NT2/D1 cells showed stem cell development (p = 5.11 × 10^−4^), cellular developmental process (p = 4.61 × 10^−4^), nervous system development (p = 1.67 × 10^−4^), multicellular organismal development (p = 6.99 × 10^−5^), system development (p = 1.94 × 10^−5^), anatomical structure development (p = 1.7 × 10^−5^), developmental process (p = 9.93 × 10^−6^), and stem cell differentiation (p = 2.09 × 10^−6^) among the highly enriched categories. GSEA analysis of the three TFs from the 41 EC and 16 SEM showed consistent results ([Figure 2](#fig2){ref-type="fig"}B). Indeed, our previous analysis of *POU5F1*, *NANOG*, and *SOX2* targets in GCT^Net^ showed that whereas *NANOG* and *POU5F1* had largely overlapping programs related to cellular organization and DNA and cellular metabolism categories, *SOX2* controlled a relatively independent program enriched for categories representing regulation of histone methylation and modification, stem cell differentiation, and a variety of differentiation-associated programs including those associated with neuronal, axonal, and chondrocyte differentiation ([@bib18]). Taken together, these results establish that functional pathways related to stem cell and neuronal development regulated by *SOX2* are curtailed in SEM but restored in EC following re-establishment of pluripotency.

*PRDM1* Does Not Regulate *SOX2* in TCam-2 and NT2/D1 Cells {#sec2.3}
-----------------------------------------------------------

A recent study showed that ectopic upregulation of *PRDM1* in the H9 hES cells and the PA-1, NTERA-2, and NCCIT EC cells led to downregulation of *SOX2* expression, suggesting direct *PRDM1* regulation of *SOX2* ([@bib21]). We investigated the potential role of *PRDM1* in regulating *SOX2* expression in TCam-2 and NT2/D1 cells, the latter as *SOX2*-expressing control, by KD of the gene in these two cell lines using the relevant SMARTpool small interfering RNAs (siRNAs) and measuring *SOX2* mRNA expression by qRT-PCR at 72 hr following KD. *SOX2* expression was neither upregulated in TCam-2 cells nor downregulated in NT2/D1 cells. We further assayed for PRDM1 and SOX2 expression by immunofluorescence (IF) in NT2/D1 and PRDM1-KD TCam-2 cells, which confirmed the mRNA analysis ([Figure 3](#fig3){ref-type="fig"}). These results show that *PRDM1* does not directly regulate *SOX2* and that some other mechanism may be involved in keeping the gene repressed in hPGCs and SEM.

*SOX2* Promoter in TCam-2 Cells Is a Target of PcG {#sec2.4}
--------------------------------------------------

We first investigated promoter methylation as a possible mechanism for *SOX2* repression in SEM. We compared the methylation status of *SOX2* promoter in bisulfite-converted DNA from five each of SEM and EC tumors along with eight EC cell lines (NT2/D1, 27X-1, NCCIT, 169A, 218A, 228A, 2101ep, TERA-1) and the TCam-2 SEM cell line, quantitating the degree of methylation by mass spectrometry of amplification products of eight primer sets that covered the entire CpG island of the *SOX2* promoter (1,000 kbp upstream and 1,000 kbp downstream of the TSS), using the Sequenom EpiTYPER assay. No methylation was detected affecting the *SOX2* promoter of SEM or EC tumors, or their derived cell lines ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B), ruling out promoter methylation as the basis for *SOX2* repression in SEM.

We then investigated the possibility of epigenetic modification as the mechanism of *SOX2* repression. In genome-wide mapping studies using human embryonic fibroblast cells, the *SOX2* promoter has previously been recognized as a target of PcG, being enriched for SUZ12 (Polycomb repressive complex 2 \[PRC2\]), CBX8 (Polycomb repressive complex 1 \[PRC1\]), and H3K27me3 ([@bib2]). To investigate whether *SOX2* promoter is a target for PcG in human germline cells, we assayed for the co-occupancy of SUZ12, BMI1 (PRC1), and H3K27me3 at the *SOX2* promoter in TCam-2 cells by ChIP-qPCR. All three components of PcG were enriched at the *SOX2* promoter, confirming epigenetic modification as the basis for its transcriptional repression in TCam-2 cells ([Figure 4](#fig4){ref-type="fig"}).

*SOX2* Transcription in TCam-2 Cells Is Regulated by *UTX* during Retinoid Signaling {#sec2.5}
------------------------------------------------------------------------------------

*UTX*, a member of the JumonjiC family TFs, is a di- and trimethyl H3K27 demethylase that also associates with mixed-lineage leukemia 2/3 (MLL) complexes possessing H3K4 methyltransferase activity; it occupies the promoters of *HOX* gene clusters and modulates their transcriptional output by regulating PRC1 and monoubiquitination of H2A in HEK 293 cells ([@bib19]). During retinoid-induced signaling in NT2/D1 cells, recruitment of *UTX* to *HOX* genes results in H3K27 demethylation and H3K4 methylation, leading to *HOXA13* and *HOXC4* gene transcription ([@bib19]). *UTX* is endogenously expressed in TCam-2 cells and we reasoned that it may regulate *SOX2* in these cells as well, when challenged to differentiate. Since retinoid signaling is known to be a major regulator of differentiation in stem cells ([@bib9]), we induced differentiation in TCam-2 cells by treatment with all-*trans* retinoic acid (RA). Western blot and IF analysis of RA-treated cells showed SOX2 expression increasing and POU5F1 and NANOG expression decreasing from day 2 to day 6 following RA treatment ([Figures 5](#fig5){ref-type="fig"}A and 5C). UTX expression remained constant in treated as well as untreated cells ([Figure 5](#fig5){ref-type="fig"}B). However, ChIP-qPCR analysis showed significant enrichment of UTX at *SOX2* promoter in day-6 RA-treated cells compared with control cells ([Figure 5](#fig5){ref-type="fig"}D).

To investigate the role of *UTX* in *SOX2* repression/derepression, we performed *UTX* KD in TCam-2 cells using SMARTpool siRNA and treated the cells with RA for 6 days, and assayed for expression of UTX and SOX2. SOX2 failed to be upregulated in response to RA in UTX-depleted cells, indicating *UTX* requirement for *SOX2* derepression ([Figures 6](#fig6){ref-type="fig"}A and 6B). We then investigated the mechanism of *UTX*-regulated *SOX2* derepression by assaying the changes in the enrichment of the histone marks H3K27me3 and H3K4me3 at the *SOX2* promoter by ChIP-qPCR in control (scramble) and UTX-KD cells following 6 days of RA treatment. As expected, the H3K27me3 mark was enriched in control cells and was reduced upon RA treatment ([Figure 6](#fig6){ref-type="fig"}C). In the *UTX*-KD cells, however, the H3K27me3 mark enrichment remained unchanged between treated and untreated cells, confirming *UTX* dependence of the repressive mark change in response to RA at the *SOX2* promoter ([Figure 6](#fig6){ref-type="fig"}C). RA treatment elicited a highly significant enrichment of the H3K4me3 mark at the *SOX2* promoter in control cells ([Figure 6](#fig6){ref-type="fig"}D). In the *UTX*-KD cells the enrichment was significant, but less than that in the control cells ([Figure 6](#fig6){ref-type="fig"}D). Although UTX is known to associate with MLL complexes that possess H3K4 methyltransferase activity, it is not known to directly regulate H3K4me3. Thus, these results overall demonstrate that recruitment of *UTX* to *SOX2* promoter in TCam-2 cells is associated with a decrease in occupancy of the repressive H3K27me3 and an increase in occupancy of the activating H3K4me3 mark, thereby enabling *SOX2* derepression in response to RA signal.

Derepression of *SOX2* Leads to Induction of Neuronal and Other Lineage Genes in TCam-2 Cells {#sec2.6}
---------------------------------------------------------------------------------------------

We obtained the GEP of day-14 RA-treated TCam-2 cells, which by now were completely differentiated morphologically, using Affymetrix U133 A plus B arrays, and analyzed the expression of marker genes related to lineage development ([Figure S2](#mmc1){ref-type="supplementary-material"}). The major lineage expressed was neuronal, with genes such as *NEFM*, *PAX6*, *NEFL*, *NESTIN*, *TUJI*, and *TRKC* showing significantly higher expression than in untreated cells. Epithelial and mesodermal genes such as *CDH1*, *EPCAM*, *FOXN1*, and *T* were downregulated in the RA-treated cells, although *KRT* was upregulated. Interestingly, several endodermal genes (*DAB2*, *NODAL*, *SPARC*) were upregulated while others (*SOX17*, *EPAS1*, *GATA4*) were downregulated. In addition, smooth muscle lineage genes such as *MEF2C* and *MYH6* were also expressed in the differentiated cells. We confirmed the GEP results on neuronal gene expression by IF analysis using NEFM, NESTIN, TUJI, and TRKC antibodies ([Figure 7](#fig7){ref-type="fig"}A). We further evaluated by qRT-PCR the status of the neuronal markers *NEUROD4*, *NEFM*, *NES*, *TRKC*, and *TUJI* in control (scramble) and UTX-KD TCam-2 cells treated with RA to test the effect of *UTX* depletion that prevented *SOX2* upregulation. The expression of each of these genes was significantly lower in the UTX-KD cells compared with control cells in response to RA treatment, confirming the role of *SOX2* in regulating neuronal gene expression ([Figure 7](#fig7){ref-type="fig"}B).

We also performed GO analysis of the expressed *SOX2* targets predicted by ARACNe in the GEP of the day-14 RA-treated TCam-2 cells. As shown in [Figure 7](#fig7){ref-type="fig"}C, the upregulated target genes represented a variety of developmental processes, with nervous system categories predominating: axonogenesis (p = 1.20 × 10^−3^), tube development (p = 1.07 × 10^−3^), gliogenesis (p = 8.03 × 10^−4^), nervous system development (p = 6.59 × 10^−4^), neuron projection regeneration (p = 6.13 × 10^−4^), axon cargo transport (p = 5.26 × 10^−4^), axon regeneration (p = 4.46 × 10^−4^), system development (p = 2.24 × 10^−4^), stem cell differentiation (p = 1.07 × 10^−4^), anterograde axon cargo transport (p = 6.84 × 10^−5^), multicellular organism development (p = 5.85 × 10^−5^), anatomical structural morphogenesis (p = 4.6 × 10^−5^), developmental process (p = 2.76 × 10^−6^), and anatomical structure development (p = 2.34 × 10^−6^). These results together confirm direct *SOX2* regulation of neuroectodermal genes.

Taken together, the data presented above are consistent with the hypothesis that *SOX2* transcription, which is repressed in TCam-2 as well as in its progenitor hPGC cells, is mediated by enrichment of PcG and H3K27me3 at its bivalent promoter and is regulated by *UTX*.

Discussion {#sec3}
==========

In this study we show that *SOX2* repression in TCam-2 cells is due to the presence of PcG and H3K27me3 at its promoter and that the repression can be reversed by recruitment of *UTX*, a H3K27 demethylase to the promoter. *SOX2* repression is a feature of hPGCs, from which SEM and other GCTs are derived by transformation and upregulation of pluripotency- and proliferation-promoting genes.

PGC specification has been investigated in the greatest detail in the mouse, where it is regulated by a PGC-specific transcriptional network composed of the TFs *Prdm1*, *Prdm14*, and *Tfap2C*, the so-called tripartite network ([@bib22], [@bib24]). Recently, human GC fate determination has been shown to be different to that of the murine GC fate ([@bib13], [@bib28]). Thus, hPGC specification is suggested to be initiated by *SOX17* and its downstream target *PRDM1*, which represses mesendodermal genes, along with extensive epigenome resetting ([@bib29], [@bib8]). Although the pluripotency factors *NANOG*, *POU5F1*, *PRDM14*, *LIN28A*, *KLF4*, and *TFP2CL1* are expressed in hPGCs as early as 5.5 weeks of gestation ([@bib29]), pluripotency is kept latent and PGCs remain unipotent or lineage restricted during their entire development.

Human fetal GCs express many of the pluripotency markers in common with murine PGCs ([@bib5]); however, of the three core pluripotency master regulators *POU5F1*, *NANOG*, and *SOX2*, only the former two are expressed whereas *SOX2* is repressed ([@bib25], [@bib29]). Nevertheless, post fertilization, human embryonic blastomeres as well as inner cell mass cells express *SOX2* ([@bib7]), implying that its repression is restricted to germline development. A recent study showed that in H9 hES cells and EC cell lines, ectopic expression of *PRDM1* led to significant reduction in *SOX2* mRNA and protein expression ([@bib21]). The same study also showed that in a ChIP assay, *PRDM1* bound to a previously identified 12-bp consensus binding site of human *SOX2* gene and that *PRDM1* suppressed the luciferase activity regulated by this genomic region. Based on these results, it was suggested that *PRDM1* regulates *SOX2* during human GC development and acts as a molecular switch to modulate between neural and germline fates ([@bib21]). However, neither the mechanism of *SOX2* repression nor its proposed *PRDM1* regulation has been demonstrated in hPGCs, GCNIS, or SEM cells, in all of which *SOX2* expression is constitutively repressed. Since TCam-2 cells are considered to be transformed hPGCs undergoing specification, we investigated the possible control of *SOX2* by *PRDM1* in TCam-2 and NT2/D1 cells, in both of which *PRDM1* is expressed. Contrary to expectation, our results of *PRDM1* silencing did not confirm its regulation of *SOX2* in either cell type. The discrepancy in results between the previous study and our study may be related to the differing contexts of cellular biology that they represented. Because the *SOX2* promoter is known to be a target of PcG in human embryonal fibroblast cells ([@bib2]), we reasoned that its regulation may also be mediated by an epigenetic modification in TCam-2 cells. Thus, after ruling out DNA methylation as the mechanism of repression, we assayed for occupancy of PRC2, PRC1, and H3K27me3 at the promoter and found enrichment, confirming their role in *SOX2* repression. We then sought to alter the enrichment of the repressive epigenetic mark at the promoter through recruitment of *UTX*, an H3K27-specific demethylase, by invoking retinoid signaling in TCam-2 cells, as was done previously in the case of the *HOX* genes in NT2/D1 cells ([@bib19]). RA treatment resulted in a change in the status of UTX and the chromatin marks at the *SOX2* promoter, leading to derepression of its transcription and induction of neuronal and other lineage genes. These results thus show that *UTX* targets *SOX2* for transcriptional regulation as in the case of *HOX* genes in human and *Drosophila* cells ([@bib19], [@bib4]). Our data also are in agreement with the idea that *SOX2* repression is an essential component of hPGC specification by preventing neuronal gene expression. Overall, then, hPGC specification appears to be mediated by three key TFs: *SOX17*, which initiates the GC lineage; *PRDM1*, which represses the mesendodermal lineage; and *SOX2*, whose repression prevents neuroectodermal lineage.

*SOX2* is an essential factor in the maintenance of both human and murine pluripotency; however, it is upregulated, along with other pluripotency factors, in murine PGCs but not hPGCs. In this study we have clarified the mechanism of its repression in the hPGC-derived TCam-2 SEM cells and suggest that the same mechanism may be responsible for *SOX2* repression in hPGCs. Although retinoids activated *SOX2* expression in TCam-2 cells, this did not result in restoration of pluripotency as indicated by the differentiated phenotype and downregulation of *POU5F1* and *NANOG* in *SOX2*-expressing TCam-2 cells. Therefore, our results are relevant specifically to *SOX2* biology in human germline, but not necessarily to re-acquisition of pluripotency in EC. The mechanism of the latter is currently unknown, perhaps requiring epigenetic modification at several loci, including *SOX2*. *SOX2* regulation overall is complex and invokes multiple pathways including the action of genes such as *POU5F1*, *NANOG*, *STAT3*, and *SMAD3* ([@bib30], [@bib31]) and, as shown previously and in this study, PcG.

Pluripotency comprises a spectrum of states that present in vitro and in vivo ([@bib10]). SEM and EC represent latent and patent versions of hPGC pluripotency; in addition, in vivo GCT pluripotency is distinct from embryonal pluripotency in being nontransient and associated with self-renewal. The functional pathways operating in SEM and EC in their respective states of pluripotency have not been characterized so far. In this study, by SAM of GEPs and GO biological process analyses of the downregulated and upregulated genes in the two subsets in comparison with normal testes, we show that whereas SEM retained pathways and processes similar to those in PGCs, EC was enriched for pathways that regulate stem cell and development categories; both subsets downregulate meiosis and spermatogenesis categories and upregulate categories associated with proliferation and self-renewal. These data provide an insight into their biology and may represent the starting point for further studies of the unique sensitivity of GCTs to DNA-damaging agents and the regulation of pluripotency and self-renewal in this tumor system.

Experimental Procedures {#sec4}
=======================

GCT and Cell Line GEPs {#sec4.1}
----------------------

We have previously reported the GEPs of 141 GCTs comprising 135 tumors of all histological types and six normal testes obtained by using Affymetrix U133 A plus B microarrays ([@bib15], [@bib16], [@bib17]). A subset of these GEPs comprising 16 SEMs and 41 ECs was used in the current analysis using previously described methods ([@bib18]). GEPs of NT2/D1 and TCam-2 cells were obtained in triplicate using the Affymetrix U133 A plus B microarrays as previously described ([@bib18]). GEP of TCam-2 cells treated with RA for 14 days were obtained from three biological replicates using Affymetrix A plus B microarrays.

Cell Lines, Cell Culture, and ATRA Treatment {#sec4.2}
--------------------------------------------

TCam-2 and NT2/D1 cells were cultured and maintained as described previously ([@bib6], [@bib12]). For RA treatment, TCam-2 cells were plated at a density of 2 × 10^6^ per 10-cm plate and treated on the following day with ATRA (10 μM/ml in medium) (Sigma-Aldrich). Cells were collected on days 0, 2, 4, and 6 for downstream experiments. Every 2--3 days, cells were reseeded in the presence of ATRA. The entire time-course experiment was carried out in triplicate with untreated cultures as controls.

IF Analysis {#sec4.3}
-----------

TCam-2 cells treated with or without ATRA were fixed in 4% paraformaldehyde. Fixed cells were permeabilized in 0.3% Triton X-100 in PBS containing 5% normal goat serum and subjected to immunocytochemical analyses as previously described ([@bib18]). Primary antibodies used for staining were goat anti-SOX2 (1:100) (catalog \#sc17319; Santa Cruz Biotechnology), rabbit anti-NANOG (1:100) (\#ab21624; Abcam), mouse anti-POU5F1 (1:200) (\#sc5279; Santa Cruz), rabbit anti-BLIMP1 (\#9115; Cell Signaling Technology), mouse anti-Nestin (\#sc23927; Santa Cruz), rabbit anti-neurofilament (\#ab-9034; Abcam), goat anti-TRKC (\#ab188592; Abcam), and mouse anti-TUJ1 (\#801201; BioLegend). Appropriate fluorescence-labeled secondary antibodies were used for visualization.

Gene Silencing Using a Transient Assay {#sec4.4}
--------------------------------------

For silencing of PRDM1 or UTX genes, 0.04 × 10^6^ TCam-2 cells were plated in 24-well plates 1 day prior to transfection. 80 nM *PRDM1* (ON-TARGETplus Human PRDM1; Dharmacon) siRNA-SMARTpool or UTX (Dharmacon) siRNA-SMARTpool and control siRNA (ON-TARGETplus Non-targeting Pool; Dharmacon) were used to transfect each well using the DharmaFECT1 Transfection Reagent (Dharmacon). Media were changed after 24 hr of transfection and cells were collected for studies at different time intervals. RNA was isolated using Qiazol lysis reagent (Qiagen) and reverse transcribed using the SuperScript VILO cDNA Synthesis Kit (Life Technologies). mRNA expression was analyzed by qRT-PCR using Taqman probes and primer sets in a 7500 Real-Time PCR system (Applied Biosystems) according to the manufacturer\'s instructions. *PGK1* mRNA level was used as internal normalization control.

SOX2 Promoter Methylation Assay by EpiTYPER Analysis {#sec4.5}
----------------------------------------------------

See [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} and [Table S3](#mmc4){ref-type="supplementary-material"}.

ChIP and ChIP-qPCR {#sec4.6}
------------------

ChIP assay was performed on TCam-2 cells according to methods previously described by us ([@bib18]). The following antibodies and reagents were used for immunoprecipitation: UTX (Abcam \#36938), SUZ12 (Millipore \#17661), BMI1 (Abcam \#14389), H3K4me3 (pAb) (Active Motif \#39159), anti-trimethyl-histone H3 (Lys 27) (Millipore \#07-449), and anti-trimethyl-histone H3 (Lys4) (Millipore \#07-437). A Dynabeads Protein G immunoprecipitation kit (Life Technologies \#10007D) was used. Immunoprecipitated DNA was purified by phenol-chloroform extraction, resuspended in 50 ml of Tris-EDTA, and amplified using oligonucleotides ([Table S3](#mmc4){ref-type="supplementary-material"}). ChIP-qPCR was performed using Power SYBR Green PCR Master Mix (Life Technologies \#4367659) on an ABI 7500 cycler.
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====================
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![ARACNe-Predicted *SOX2* Targets Are Enriched in NT2D/1 Cells and EC Compared with TCam-2 Cells and SEM\
(A) GSEA enrichment analysis of targets of (a) *SOX2* (p = 0.05), (b) *POU5F1* (p = 0.04), and (c) *NANOG* (p = 0.0) in TCam-2 versus NT2/D1 cells.\
(B) GSEA enrichment analysis of targets in EC versus SEM of (a) *SOX2* (0.027), (b) *POU5F1* (0.5), and (c) *NANOG* (0.4). All p values are by two-tailed t test.](gr2){#fig2}

![*SOX2* Expression Is Not Altered in *PRDM1*-KD TCam-2 Cells\
(A) qRT-PCR analysis of (a) *PRDM1* and (b) *SOX2* expression in *PRDM1*-KD cells following normalization to *PGK1* signal. Data represent mean ± SD of three independent experiments. ^∗∗∗^p \> 0.001 by Student's t test; ns, not significant.\
(B) Representative IF images of (a) NT2D-1, (b) TCam-2, and (c) PRDM1-KD TCam-2 cells stained for DAPI (blue), PRDM1 (green), and SOX2 (red), and merged images. Scale bars represent 100 μm.](gr3){#fig3}

![PcG Proteins SUZ12 and BMI1 and the Repressive Chromatin Mark H3K27me3 Are Enriched at *SOX2* Promoter in TCam-2 Cells\
ChIP analyses were performed using antibodies for (A) SUZ12, (B) BMI1, (C) H2K27me3, or immunoglobulin G (IgG) (as nonspecific control) in Tcam-2 cells. Plotted values are relative enrichment to 10% input and measured for indicated site in the *SOX2* promoter and *GUSB* (β-glucuronidase) gene (control). Data represent mean ± SD of three independent experiments. Student's t test: ns, not significant; ^∗∗^p \< 0.01; ^∗^p \< 0.05.](gr4){#fig4}

![SOX2 Is Expressed in TCam-2 Cells following RA Treatment\
(A) Immunoblot of RA-treated and untreated cells showing increased SOX2 (35 kDa) expression and decreased POU5F1 (39 kDa) and NANOG (34 kDa) expression over a 6-day time course. Tubulin (50 kDa) is loading control.\
(B) Immunoblot showing unchanged UTX (150 kDa) expression over a 6-day time course. Tubulin (50 kDa) is loading control.\
(C) IF showing SOX2, POU5F1, and NANOG expression following RA treatment. (a) Untreated TCam-2 cells showing POU5F1 (green), NANOG (magenta), and DAPI (blue), but not SOX2 (red) expression. (b) RA-treated TCam-2 cells showing SOX2 but not POU5F1 and NANOG expression. BF is brightfield image. Scale bars represent 100 μm.\
(D) RA-treated and untreated TCam-2 cells were subjected to ChIP-qPCR using UTX antibody or an IgG antibody (nonspecific control). The immunoprecipitated DNA was subjected to PCR using primers specific to the *SOX2* promoter region. Data represent mean ± SD of three independent experiments. Student's t test: ns, not significant; ^∗∗^p \< 0.01; ^∗^p \< 0.05.](gr5){#fig5}

![Epigenetic Modifications of *SOX2* Promoter Leading to RA-Induced Derepression Are Modulated by UTX\
(A) Expression of SOX2, POU5F1, and NANOG in the RA-treated UTX-KD cells compared with scramble (scr) cells in a 6-day time-course experiment.\
(B) qRT-PCR showing expression level of *SOX2*, *NANOG*, *POU5F1*, and *UTX* in the untreated scr versus UTX-KD cells and treated scr versus UTX-KD cells. Data represent mean ± SD of the three independent experiments. ^∗∗^p \< 0.01 between treated UTX-KD and scr by Student's t test.\
(C) ChIP-qPCR showing loss of H3K27me3 enrichment at SOX2 promoter of RA-treated scr cells compared with untreated cells, whereas the enrichment is unchanged in RA-treated UTX-KD cells. Data represent mean ± SD of three independent experiments. Student's t test: ns, not significant; ^∗∗^p \< 0.01; ^∗^p \< 0.05.\
(D) ChIP-qPCR with H3K4me3 antibody showing enrichment at SOX2 promoter of RA-treated scr cells compared with untreated scr cells and RA-treated UTX-KD cells compared with untreated KD cells. Data represent mean ± SD of three independent experiments. Student's t test: ns, not significant; ^∗∗^p \< 0.01; ^∗^p \< 0.05.](gr6){#fig6}

![Neuronal Marker Genes Are Upregulated following SOX2 Derepression in TCam-2 Cells in Response to Retinoid Signaling\
(A) Representative IF showing staining with (a) neurofilament (NEFM), (b) nestin (NES), (c) neuron-specific class III β-tubulin (TUJI), and (d) neurotrophic tyrosine kinase receptor type 3 (TRKC). Left image, DAPI; middle image, neuronal gene; right image, merged. For each antibody the upper panel represents untreated cells and the lower panel RA-treated cells. Scale bars represent 100 μm.\
(B) Expression of neuronal genes in RA-treated UTX-KD cells compared with RA-treated scramble cells by qRT-PCR. Data represent mean ± SD of three independent experiments. ^∗∗^ p \< 0.01, ^∗^p \< 0.05 by Student's t test.\
(C) GO categories enriched in ARACNe-predicted SOX2 targets of TCam-2 cells following RA treatment. Blue bar represents actual enriched number of genes; red bar represents expected enrichment by chance.](gr7){#fig7}
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